BTCRC-LUN17-127 published in Lung Cancer Journal
A Big Ten Cancer Research Consortium study on plinabulin combined with nivolumab and ipilimumab for recurrent small cell lung cancer was published in Lung Cancer Journal. The study, BTCRC-LUN17-127, found the combination tolerable at 30 mg/m², though median progression-free survival was 1.6 months, below the target of 3.5 months. Some patients showed prolonged response.
Related Clinical Trials
Highlighted Terms
University of Illinois Hospital & Health Sciences SystemBig Ten ConferenceBig Ten Cancer Research Consortiumsmall cell lung cancer (SCLC)H. Lee Moffitt Cancer Center and Research InstituteIndiana University Melvin and Bren Simon Comprehensive Cancer CenterplinabulinUniversity of MinnesotanivolumabipilimumabRutgers Cancer Institute of New JerseyNCT03575793City of Hope National Medical Center
Related News
BTCRC-LUN17-127 published in Lung Cancer Journal
A Big Ten Cancer Research Consortium study on plinabulin combined with nivolumab and ipilimumab for recurrent small cell lung cancer was published in Lung Cancer Journal. The study, BTCRC-LUN17-127, found the combination tolerable at 30 mg/m², though median progression-free survival was 1.6 months, below the target of 3.5 months. Some patients showed prolonged response.